Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y. Fujita K, et al. Among authors: miwa k. Cancer Sci. 2008 May;99(5):1049-54. doi: 10.1111/j.1349-7006.2008.00773.x. Cancer Sci. 2008. PMID: 18380793 Free PMC article. Clinical Trial.
Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Fujita K, Nakayama H, Ichikawa W, Yamamoto W, Endo H, Nagashima F, Tanaka R, Miya T, Sunakawa Y, Yamashita K, Mizuno K, Ishida H, Araki K, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Hirose T, Sasaki Y. Fujita K, et al. Among authors: miwa k. Drug Metab Dispos. 2009 Jul;37(7):1375-7. doi: 10.1124/dmd.109.027052. Epub 2009 Apr 23. Drug Metab Dispos. 2009. PMID: 19389859
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: miwa k. Cancer Chemother Pharmacol. 2011 Aug;68(2):279-84. doi: 10.1007/s00280-010-1485-8. Epub 2010 Oct 19. Cancer Chemother Pharmacol. 2011. PMID: 20957480
Delayed elimination of SN-38 in cancer patients with severe renal failure.
Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y. Fujita K, et al. Among authors: miwa k. Drug Metab Dispos. 2011 Feb;39(2):161-4. doi: 10.1124/dmd.110.035451. Epub 2010 Oct 27. Drug Metab Dispos. 2011. PMID: 20980446 Clinical Trial.
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Sunakawa Y, Fujita K, Ichikawa W, Ishida H, Yamashita K, Araki K, Miwa K, Kawara K, Akiyama Y, Yamamoto W, Nagashima F, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: miwa k. Oncology. 2012;82(4):242-8. doi: 10.1159/000337225. Epub 2012 Apr 12. Oncology. 2012. PMID: 22508373 Clinical Trial.
1,230 results